Sipuleucel-T in prostate cancer: Indication of added benefit – Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T.
Cigarette smoking is even more deadly than you think — US Smoking deaths may be underestimated: Study – A new study suggests that current estimates significantly underestimate the number of Americans who die from cigarette smoking. The Surgeon General estimates that each year, smoking kills about 480,000 Americans.
Drug Combination Extends Survival by More Than a Year in Metastatic Prostate Cancer – Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug docetaxel as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers.
Chronic inflammation may be linked to aggressive prostate cancer — Chronic inflammation linked to ‘high-grade’ prostate cancer – Men who show signs of chronic inflammation in non-cancerous prostate tissue may have nearly twice the risk of actually having prostate cancer than those with no inflammation.
Melatonin may lower prostate cancer risk – Higher levels of melatonin, a hormone involved in the sleep-wake cycle, may suggest decreased risk for developing advanced prostate cancer. Melatonin is a hormone that is produced exclusively at night in the dark and is an important output of the circadian rhythm, or the body’s inherent 24-hour clock.
Compound in grapes, red wine could help treat multiple types of cancer, study finds – A recent study by a University of Missouri researcher shows that resveratrol, a compound found in grape skins and red wine, can make certain tumor cells more susceptible to radiation treatment.
Prostate cancer: A change in circulating tumor cells detection has high potential in the prediction – A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen levels.
Use of ADT For Treatment of Prostate Cancer Linked With Increased Risk of Kidney Injury – Androgen deprivation therapy (ADT) for nonmetastatic prostate cancer was associated with a significantly increased risk of acute kidney injury, according to a study that included more than 10,000 men published in JAMA.
Study confirms link between omega-3 fatty acids and increased prostate cancer risk — Consumption of fatty fish and fish-oil supplements linked to 71 percent higher risk – A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center has confirmed the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer.
Observation is safe, cost-saving in low-risk prostate cancer — Study suggests low-risk patients can forego immediate treatment – Many men with low-risk, localized prostate cancers can safely choose active surveillance or “watchful waiting” instead of undergoing immediate treatment and have better quality of life while reducing health care costs, according to a study by researchers at Dana-Farber Cancer Institute and Massachusetts General Hospital.